Febuxostat

Drug Profile

Febuxostat

Alternative Names: Adenuric; Feburic; Febuxostat XR; TEI-6720; TMX 67XR; TMX-67; Uloric

Latest Information Update: 19 Jun 2017

Price : $50

At a glance

  • Originator Teijin Pharma
  • Developer Astellas Pharma; Ipsen; Menarini; SK Chemicals; Takeda Pharmaceuticals USA; Teijin Pharma
  • Class Antigouts; Carboxylic acids; Nitriles; Phenyl ethers; Small molecules; Thiazoles
  • Mechanism of Action Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperuricaemia
  • Registered Tumour lysis syndrome
  • Phase II Hypertension
  • Suspended Angina pectoris

Most Recent Events

  • 10 May 2017 Discontinued - Phase-III for Hyperuricaemia (in patients with gout) in USA (PO,Controlled-release) before May 2017 (Takeda FY2016 results, May 2017)
  • 22 Feb 2017 Phase-I/II clinical trials in Tumour lysis syndrome (In adolescents, In children, Prevention, In adults) in Bulgaria and Hungary (PO) after February 2017 (EudraCT2016-001445-61)
  • 22 Feb 2017 Phase-I/II clinical trials in Tumour lysis syndrome (Prevention, In children, In adults, In adolescents) in Spain (PO) (EudraCT2016-001445-61)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top